Trials / Suspended
SuspendedNCT00777816
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
A Blinded, Placebo-controlled, Study of the Safety and Pharmacokinetics of XOMA 052 Administered to Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study X052070 will evaluate the safety and pharmacokinetics (PK) of XOMA 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (RA). It is hypothesized that administration of XOMA 052 is likely to improve inflammatory control in subjects with RA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XOMA 052 | A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection. |
| DRUG | Placebo | A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection. |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2014-10-01
- First posted
- 2008-10-22
- Last updated
- 2015-12-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00777816. Inclusion in this directory is not an endorsement.